A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Emerging evidence indicates the presence of low-grade mucosal inflammation and its
pathogenetic role in IBS. The aim of this pilot study is to provide that mesalazine treatment
of IBS patients reduces low grade colonic inflammation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
SOFAR S.p.A.
Collaborators:
IRCCS Azienda Ospedaliero-Universitaria di Bologna St. Orsola Hospital